Bicara Therapeutics Inc (NASDAQ: BCAX) on Monday, soared 4.84% from the previous trading day, before settling in for the closing price of $9.71. Within the past 52 weeks, BCAX’s price has moved between $7.80 and $28.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 41.07%. With a float of $32.77 million, this company’s outstanding shares have now reached $54.53 million.
In an organization with 55 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Bicara Therapeutics Inc (BCAX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Bicara Therapeutics Inc is 39.92%, while institutional ownership is 62.40%. The most recent insider transaction that took place on Jun 16 ’25, was worth 165,096. In this transaction Chief Legal Officer of this company sold 15,829 shares at a rate of $10.43, taking the stock ownership to the 0 shares. Before that another transaction happened on Jun 16 ’25, when Company’s Officer proposed sale 31,658 for $10.84, making the entire transaction worth $343,173.
Bicara Therapeutics Inc (BCAX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 41.07% per share during the next fiscal year.
Bicara Therapeutics Inc (NASDAQ: BCAX) Trading Performance Indicators
Bicara Therapeutics Inc (BCAX) is currently performing well based on its current performance indicators. A quick ratio of 24.62 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -2.70 in one year’s time.
Technical Analysis of Bicara Therapeutics Inc (BCAX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.37 million. That was inferior than the volume of 0.66 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 82.74%.
During the past 100 days, Bicara Therapeutics Inc’s (BCAX) raw stochastic average was set at 26.80%, which indicates a significant decrease from 79.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.65 in the past 14 days, which was lower than the 1.24 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.26, while its 200-day Moving Average is $15.41. However, in the short run, Bicara Therapeutics Inc’s stock first resistance to watch stands at $10.67. Second resistance stands at $11.16. The third major resistance level sits at $11.70. If the price goes on to break the first support level at $9.64, it is likely to go to the next support level at $9.10. The third support level lies at $8.61 if the price breaches the second support level.
Bicara Therapeutics Inc (NASDAQ: BCAX) Key Stats
Market capitalization of the company is 555.18 million based on 54,536K outstanding shares. Right now, sales total 0 K and income totals -68,000 K. The company made 0 K in profit during its latest quarter, and -36,850 K in sales during its previous quarter.
